Priming with r-metHuSCF and filgrastim or chemotherapy and filgrastim in patients with malignant lymphomas: A randomized phase II pilot study of mobilization and engraftment

Bone Marrow Transplantation

Volumn 46, Issue 1, 2011, Pages 44-51

  Johnsen, H E ^a,b   Geisler, C ^c   Juvonen, E ^d   Remes, K ^e   Juliusson, G ^f   Hornsten P ^g   Kvaloy, S ^h   Kvalheim, G ^h   Jurgensen G W ^b   Pedersen, L M ^b   Bergmann, O J ^b   Schmitz, A ^a   Boegsted, M ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c Rigshospitalet   (Denmark)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e TURKU UNIVERSITY HOSPITAL   (Finland)

^f LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^g UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^h OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

clinical trial; lymphoma; mobilization; priming; SCF

Indexed keywords

CARMUSTINE; CYTARABINE; DIPHENHYDRAMINE; ETOPOSIDE; MELPHALAN; PSEUDOEPHEDRINE; RANITIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT STEM CELL FACTOR; SALBUTAMOL;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CYTOPENIA; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; ENGRAFTMENT; ERYTHEMA; FEMALE; FLOW CYTOMETRY; HEMATOLOGIC DISEASE; HUMAN; INJECTION SITE REACTION; LEUKAPHERESIS; LIVER FAILURE; LYMPHOMA; MALE; MULTICENTER STUDY; MUSCULOSKELETAL INJURY; MYELOABLATIVE CONDITIONING; NAUSEA; NEUTROPENIA; PAIN; PERIPHERAL BLOOD STEM CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RIGOR; SEIZURE; STEM CELL MOBILIZATION; THROMBOCYTOPENIA; URINARY TRACT DISEASE; VOMITING;

ADULT; AGED; ANTIGENS, CD34; DRUG THERAPY, COMBINATION; FEMALE; FILGRASTIM; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PILOT PROJECTS; RECOMBINANT PROTEINS; STEM CELL FACTOR; THROMBOCYTOPENIA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 78651367020     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.84     Document Type: Article

References (33)

1. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 33: 1540-1545.
2. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A et al. Dose intensification with autologous bonemarrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
3. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233-2258.
4. Sheridan WP, Begley CG, Juttner CA, Szer J, Bikto L, Maher D et al. Effect of peripheral blood progenitor cells mobilized by Filgrastim (G-CSF) on platelet recovery after high dose chemotherapy. Lancet 1992; 339: 640-644.
5. Shpall E, Champlin R, Glaspy JA. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998; 4: 84-92.
6. Bensinger WI, Longin K, Appelbaum F, Rowley S, Weaver C, Lilleby K et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (r-met HuG-CSF): An analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831.
7. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L et al. An analysis of engraftment kinetics as a function of the CD34+ content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
8. Serke S, Johnsen HE. A European reference protocol for quality assessment and clinical validation of autologous haematopoietic blood progenitor and stem cell grafts. Bone Marrow Transplant 2001; 27: 463-470.
9. Baech J, Roer O, Johnsen HE. Individual quality assessment of autografting by probability evaluation: A model estimated by analysis of graft-related end points in 204 patients with malignancies. Bone Marrow Transplant 2003; 31: 453-458.
10. Knudsen LM, Gaarsdal E, Jensen L, Nikolaisen K, Johnsen HE. Evaluation of mobilized CD34+ cell counts to guide timing and yield of large-scale collection by leukapheresis. J Hematother 1998; 7: 45-52.
11. Meldgaard Knudsen L, Jensen L, Gaarsdal E, Nikolaisen K, Johnsen HE. A comparative study of sequential priming and mobilisation of progenitor cells with rhG-CSF alone and high-dose cyclophosphamide plus rhG-CSF. Bone Marrow Transplant 2000; 26: 717-722.
12. Bernstein ID, Andrews RG, Zsebo KM. Recombinant human stem cell factor enhances the formation of colonies by CD34+ and CD34+lin- cells, and the generation of colony-forming cell progeny from CD34+lin- cells cultured with interleukin-3, granulocyte colony-stimulating factor, or granulocyte-macrophage colony-stimulating factor. Blood 1991; 77: 2316-2321.
13. McNiece IK, Langley KE, Zsebo KM. Recombinant human stem cell factor synergises with GM-CSF, G-CSF, IL-3 and Epo to stimulate human progenitor cells of the myeloid and erythroid lineages. Exp Hematol 1991; 19: 226-231.
14. Briddell RA, Hartley CA, Smith KA, McNiece IK. Recombinant rat stem cell factor synergizes with recombinant human granulocyte colony-stimulating factor in vivo in mice to mobilize peripheral blood progenitor cells that have enhanced repopulating potential. Blood 1993; 82: 1720-1723.
15. McNiece IK, Briddell RA, Hartley CA, Smith KA, Andrews RG. Stem cell factor enhances in vivo effects of granulocyte colony stimulating factor for stimulating mobilization of peripheral blood progenitor cells. Stem Cells 1993; 11(Suppl 2): 36-41.
16. de Revel T, Appelbaum FR, Storb R, Schuening F, Nash R, Deeg J et al. Effects of granulocyte colony-stimulating factor and stem cell factor, alone and in combination, on the mobilization of peripheral blood cells that engraft lethally irradiated dogs. Blood 1994; 83: 3795-3799.
17. Andrews R, Briddell R, Knitter G, Opie T, Bronsden M, Myerson D et al. In vivo synergy between recombinant human stem cell factor and recombinant human granulocyte colonystimulating factor in baboons: Enhanced circulation of progenitor cells. Blood 1994; 84: 800-810.
18. Shpall EJ, Wheeler CA, Turner SA, Yanovich S, Brown RA, Pecora AL et al. A randomized phase 3 study of PBPC mobilization with stem cell factor and Filgrastim in high-risk breast cancer patients. Blood 1999; 93: 2491-2501.
19. Glaspy JA, Shpall EJ, LeMaistre CF, Briddell RA, Menchaca DM, Turner SA et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with Filgrastim in breast cancer patients. Blood 1997; 90: 2939-2951.
20. Moskowitz CH, Stiff P, Gordon MS, McNiece I, Ho AD, Costa JJ et al. Recombinant methionyl human stem cell factor and Filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients. Results of a phase I/II trial. Blood 1997; 89: 3136-3147.
21. Tricot G, Jagannath S, Desikan KR, Siegel D, Munshi N, Olson E et al. Superior mobilization of peripheral blood progenitor cells (PBPC) with r-metHuSCF (SCF) and r-metHuG-CSF (Filgrastim) in heavily pretreated multiple myeloma (MM) patients. Blood 1996; 88(Suppl 1): 388a (abstract).
22. Weaver A, Ryder D, Crowther D, Dexter TM, Testa NG. Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor. Blood 1996; 88: 3323-3328.
23. Weaver A, Testa NG. Stem cell factor leads to reduced blood processing during apheresis or the use of whole blood aliquots to support dose-intensive chemotherapy. Bone Marrow Transplant 1998; 22: 33-38.
24. Begley CG, Basser R, Mansfield R, Thomson B, Parker WRL, Layton J et al. Enhanced levels and enhanced clonogenic capacity of blood progenitor cells following administration of stem cell factor plus granulocyte colony-stimulating factor to humans. Blood 1997; 90: 3378-3389.
25. Stiff P, Gingrich R, Luger S, Brown RA, LeMaistre CF, Perry J et al. Improved PBPC collection using Stemgen (stem cell factor) and Filgrastim (G-CSF) compared to G-CSF alone in heavily pretreated lymphoma and Hodgkin's disease patients. Blood 1997; 90(Suppl 1): 591a (abstract).
26. Facon T, Harousseau JL, Maloisel F, Attal M, Odriozola J, Alegre A et al. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: A randomized, controlled trial. Blood 1999; 94: 1218-1225.
27. Johnsen HE, Baech J, Nikolajsen K. Validation of the Nordic flow cytometry standard for CD34+ cell enumeration in blood and autografts: Report from the third workshop. Nordic Stem Cell Laboratory Group. J Hematother 1999; 8: 15-28.
28. Johnsen HE, Knudsen LM. Nordic flow cytometry standards for CD34+ cell enumeration in blood and leukapheresis products: Report from the second Nordic Workshop. Nordic Stem Cell Laboratory Group (NSCL-G). J Hematother 1996; 5: 237-245.
29. Johnsen HE. Report from a Nordic workshop on CD34+ cell analysis: Technical recommendations for progenitor cell enumeration in leukapheresis from multiple myeloma patients. Nordic Myeloma Study Group Laboratories. J Hematother 1995; 4: 21-28.
30. Herbert KE, Morgan S, Prince HM, Westerman DA, Wolf MM, Carney DA et al. Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: Results of a phase II study with an historical comparator. Leukemia 2009; 23: 305-312.
31. To LB, Bashford J, Durrant S, MacMillan J, Schwarer AP, Prince HM. et al. Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim. Bone Marrow Transplant 2003; 31: 371-378.
32. Prósper F, Solá C, Hornedo J, Arbona C, Menéndez P, Orfao A et al. Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer previously treated with chemotherapy. Leukemia 2003; 17: 437-441.
33. Stiff P, Gingrich R, Luger S, Wyres MR, Brown RA, LeMaistre CF et al. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 2000; 26: 471-481.